Cure My Disease

Don't miss your cure!

 Log in / Sign up

New therapy aims to quiet the fear that haunts cancer survivors

NCT ID NCT07500168

Not yet recruiting Symptom relief Sponsor: Koo Foundation Sun Yat-Sen Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

Many cancer survivors live with a persistent fear that their cancer will return, which can harm their mental health and daily life. This pilot study will test a type of talking therapy called metacognitive therapy (MCT) against relaxation therapy in 120 survivors. The goal is to see if MCT can reduce that fear and improve overall well-being.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
metacognitive therapy (a structured psychological intervention)
What this could lead to
If it works, this could provide an effective psychological tool to help cancer survivors manage fear of recurrence and improve quality of life.
What could go wrong
This is a small pilot study, not yet recruiting. Results may not apply to all survivors, and the therapy may not prove more effective than relaxation techniques.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER SURVIVORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anxiety disorder cancerophobia Depression

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER SURVIVORS FEAR OF CANCER RECURRENCE PSYCHOLOGICAL DISTRESS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Koo Foundation Sun Yat-Sen Cancer Center

    Taipei, Taipei, 112, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.